Alexza Pharmaceuticals ALXA
-
Alexza ( ALXA ) -34.4% premarket after it says its new drug application for Adasuve, a schizophrenic and bipolar disorder treatment, can't be approved by the FDA until a deficiency at a manufacturing ...
Alexza ( ALXA ) -34.4% premarket after it says its new drug application for Adasuve, a schizophrenic and bipolar disorder treatment, can't be approved by the FDA until a deficiency at a manufacturing facility for the application is resolved. 1 comment!
-
UPDATE 1-FDA declines to approve Alexza's schizophrenia drug
May 3 (Reuters) - Alexza Pharmaceuticals Inc said U.S. health regulators failed to approve its experimental treatment to calm patients with schizophrenia or bipolar disorder, sending its shares down...
-
Thursday's Bio-Pharma Drug Approval And Catalyst Event List
… data of ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection. The data from this trial is due to come out by early June. Alexza Pharma ( ALXA ) 5/2/12 pps: $0.69. Market cap: $80.13M Complete Story »
-
12 Healthcare Companies Expecting May Catalysts
By Spencer Knight : As a rocky month of April comes to a close, the month of May looks to be very exciting for the Healthcare and Biotech sectors. There are 14 events scheduled for May, including a few very high profile treatments. Healthcare and particularly biotech trading can be very lucrative
-
Biotech-Focused Star Hedge Fund Tang Capital's Q1 2012 Picks In Its $429 Million Portfolio
By Ganaxi Small Cap Movers : San Diego, CA-based Tang Capital Management, founded in 2002 by Kevin C. Tang is a hedge fund that specializes in the life sciences industry. Prior to founding his firm, Mr. Tang was most recently the Managing Director and head of Life Sciences research group at ...
-
Pivotal FDA Decision Upcoming For Alexza
By Jason Napodano : On May 4, 2012, the U.S. FDA is expected to rule on the approval of Alexza Pharmaceuticals ' ( ALXA ) Adasuve (Staccato loxapine) for the treatment of acute agitation in patients with schizophrenia and …
-
6 Biotech Stocks With Huge Potential In May
By StockPandit : So far, 2012 has been the best year for the Biotechnology and Drugs industry. So many stocks surged in the last three months based on clinical trial results, U.S. Food and Drug Administration (FDA) approval, FDA Advisory Committee's recommendation, European commission approval, ...
-
Alexza Pharmaceuticals ([[ ALXA ]] -0.4%) faces a cash crunch even after a public offering of shares, corporate restructuring including layoffs, and a new partnership. The company warns that at its ...
Alexza Pharmaceuticals ( ALXA -0.4% ) faces a cash crunch even after a public offering of shares, corporate restructuring including layoffs, and a new partnership . The company warns that at its current burn rate it will empty its bank account in Q4. Post your comment!
-
Shares of Alexza Pharmaceuticals ( ALXA ) jump after hours as Grupo Ferrer agrees to buy 2.4M shares of Alexza stock at $1.24 per share, more than double the pharmaceutical company's $0.60 closing ...
Shares of Alexza Pharmaceuticals ( ALXA ) jump after hours as Grupo Ferrer agrees to buy 2.4M shares of Alexza stock at $1.24 per share, more than double the pharmaceutical company's $0.60 closing price. Shares +15% AH. Post your comment!
-
VIX - Options Volatility Sonar: Wednesday Recap
By Erick McKitterick : VIX - Market Sentiment: Wednesday S&P futures were poised to bounce after the terrible price action from Tuesday. Apple (APPL) was set for a press release to announce the new iPad 3 along with positive news out of Europe had the markets bouncing today. Price action moved to